Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-29
2007-05-29
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S423000, C548S492000, C548S506000, C548S510000, C548S516000
Reexamination Certificate
active
11273479
ABSTRACT:
Novel compounds are provided which are glycogen phosphorylase inhibitors which are useful in treating, preventing or slowing the progression of diseases requiring glycogen phosphorylase inhibitor therapy such as diabetes and related conditions (such as hyperglycemia, impaired glucose tolerance, insulin resistance and hyperinsulinemia), the microvascular complications associated with diabetes (such as retinopathy, neuropathy, nephropathy and delayed wound healing), the macrovascular complications associated with diabetes (cardiovascular diseases such as atherosclerosis, abnormal heart function, myocardial ischemia and stroke), as well as Metabolic Syndrome and its component conditions including hypertension, obesity and dislipidemia (including hypertriglyceridemia, hypercholesterolemia and low HDL), and other maladies such as non-cardiac ischemia, infection and cancer. These novel compounds have the structureor stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, R1and R2are defined herein.
REFERENCES:
patent: 5952322 (1999-09-01), Hoover et al.
patent: 5998463 (1999-12-01), Hulin et al.
patent: 6589970 (2003-07-01), Commons et al.
patent: 6660742 (2003-12-01), Lee
patent: 2001/0046958 (2001-11-01), Treadway
patent: 2003/0073731 (2003-04-01), Lee
patent: 2004/0002495 (2004-01-01), Sher et al.
patent: 0 624 575 (1994-11-01), None
patent: 978 279 (2000-02-01), None
patent: 1 041 068 (2000-10-01), None
patent: 1 149 580 (2001-01-01), None
patent: 1 088 824 (2001-04-01), None
patent: 1 136 071 (2001-09-01), None
patent: 1 177 791 (2002-02-01), None
patent: 9-100278 (1997-04-01), None
patent: 2004-196702 (2004-07-01), None
patent: WO 96/39384 (1996-12-01), None
patent: WO 96/39385 (1996-12-01), None
patent: WO 99/26659 (1999-06-01), None
patent: WO 99/43663 (1999-09-01), None
patent: WO 00/15645 (2000-03-01), None
patent: WO 00/47206 (2000-08-01), None
patent: WO 01/23347 (2001-04-01), None
patent: WO 01/32622 (2001-05-01), None
patent: WO 02/20530 (2002-03-01), None
patent: WO 02/064546 (2002-08-01), None
patent: WO 02/064565 (2002-08-01), None
patent: WO 03/035621 (2003-05-01), None
patent: WO 03/037864 (2003-05-01), None
patent: WO 03/072570 (2003-09-01), None
patent: WO 03/074484 (2003-09-01), None
patent: WO 03/074513 (2003-09-01), None
patent: WO 03/074531 (2003-09-01), None
patent: WO 03/074532 (2003-09-01), None
patent: WO 03/091213 (2003-11-01), None
patent: WO 03/104188 (2003-12-01), None
patent: WO 04/041780 (2004-05-01), None
patent: WO 04/072060 (2004-08-01), None
patent: WO 04/078743 (2004-09-01), None
Proc. Natl. Acad. Sci. USA 1998, 95, 1776-1781.
J. Med. Chem. 1998, 41, 2934-2938.
Exp. Opin. Invest. Drugs 2001, 10, 439-454.
J. Med. Chem. 2002, 45, 1002-1018.
Journal of Pharmaceutical Sciences, vol. 64(6), 1975, 1001-1005.
Ellsworth Bruce A.
Meng Wei
Sher Philip M.
Washburn William N.
Bogie Terence J.
Bristol--Myers Squibb Company
Chu Yong
Saeed Kamal A.
LandOfFree
2-aminonaphthalene derivatives and related glycogen... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-aminonaphthalene derivatives and related glycogen..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-aminonaphthalene derivatives and related glycogen... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3761789